ALA Share Price Performance
AU$0.10
-0.04 (-31.03%)
Price AU$0.10
Share PriceAU$0.10
ALA Community Narratives
There are no narratives available yet.
Recent ALA News & Updates
No updates
Arovella Therapeutics Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0053
- Gross Margin
- 100.00%
- Net Profit Margin
- -181.62%
- Debt/Equity Ratio
- 0%
Arovella Therapeutics Limited Competitors
About ALA
- Founded
- 1999
- Employees
- n/a
- CEO
- WebsiteView website
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Australian Market Performance
- 7 Days: 0.7%
- 3 Months: 7.6%
- 1 Year: 14.0%
- Year to Date: 6.4%
Over the last 7 days, the market has remained flat, although notably the Consumer Discretionary sector gained 3.1% in that time. More promisingly, the market is up 14% over the past year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading